Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04982237 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

StatusActive, Not Recruiting
PhasePhase 3
SponsorAkeso
Started2021-08-27
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 19, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2025-11-17
Study Status v3
Primary completion date2025-04-01→2025-12-30
2025-02-28
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations, References v2
Trial statusRecruiting→Active, Not Recruiting
Enrollment targetestimated 440→confirmed 445
Study sitesdetails revised at 5 of 5 sites
2022-04-26
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2021-07-30→confirmed 2021-08-27
Study sites7→5
2021-07-21
Original filing
Akeso
96 trials monitored
See 1 trial at risk
Cervical Cancer
853 trials monitored
See 46 trials at risk
This is A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate AK104 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Trial Details
NCT Number NCT04982237
Lead Sponsor Akeso
Conditions Cervical Cancer
Enrollment 445 participants
Start Date 2021-08-27
Primary Completion 2025-12-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-11-19